Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB009471 Monotherapy in HIV-1
NCT00393120Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenicriviroc in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Incyte. Primary endpoints: Safety and tolerability assessed by monitoring adverse experiences at Day 42 and Pharmacokinetics of INCB009471 at 14 days. Started Oct 2006; status: completed.
02
Drugs
cenicriviroc
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00393120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00393120.